Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c9c874f08f5717f2aedec0310b959320 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-60 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2015-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2017-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f10065a7e3b8c0a10b1d9b19a0f8d504 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7dfc3d07ab1111975e9ca9c0c2f38ac5 |
publicationDate |
2017-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9795660-B2 |
titleOfInvention |
Id-protein targeted tumor cell vaccine |
abstract |
ID Protein targeted cancer immunotherapy. The invention provides a cell-based attenuated live tumor cell vaccine that safely produces broad cellular tumor-specific immunity, protects against tumor formation in prophylactic tumor models, and in combination with the clinically relevant immune modulator s such as antibodies to CTLA-4 or antibodies to PD-L1 can destroy established tumors in mammals. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11278225-B2 |
priorityDate |
2014-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |